North America Live attenuated vaccines Market

The North American live attenuated animal vaccine market, mainly driven by growing prevalence of Animal Diseases, was valued at $805 million in 2013, and expected to reach $999 million by 2018 at a CAGR of 4.4%. Live attenuated vaccines for poultry have a dominant share compared to the rest, since the spray method is more popularly used for poultry vaccinations.

‘The North American Live Attenuated Animal Vaccine Market, 2012-2018’ analyzes the market by 6 Products such as aquaculture, companion animal vaccines, equine, livestock, porcine, and poultry. Types of live attenuated market are preventive and therapeutic. The live attenuated market experiences a positive growth till 2018 owing to its presence and requirement in all the segments.

Live attenuated vaccines are relatively easy to create for certain viruses. Vaccines against measles, mumps, and Varicella (chickenpox), for example, are made by Live attenuated vaccines method. Rubella (MMR combined vaccine), Influenza (nasal spray), and Rotavirus are some other examples. The Univax-BD, Univax Plus, Trachivax, Shor-Bron-D, and Vista Once SQ are a few examples of live attenuated vaccines.

North America accounts for the second-largest share in the live attenuated vaccine market. The rise in companion and farm animal and an increase in investments by companies helped to boost the market in the region. The demand in the U.S. for animal health products is expected to rise 3.9% annually to almost $13 billion in 2016. Gains in all product segments will be at least incrementally improved from those during the recession-impacted 2006 to 2011 period. Preventive care will remain a driving factor in sales of animal health products as owners of commercial and companion animals alike recognize the need to maintain good health conditions for their animals.

The report also provides an extensive competitive landscaping of companies operating in live attenuated market. The main companies in Live Attenuated vaccine market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. Segment and country-specific company shares, news & deals, mergers and acquisitions, segment-specific pipeline products, product approval, and product recalls of the major companies have been detailed in the report.

Customization Options

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:

Product Analysis

• Usage pattern (in-depth trend analysis) of products (segment wise)
• Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment level
• End-user adoption rate analysis of the products (segment wise and country wise)
• Comprehensive coverage of product approvals, pipeline products and product recalls

Epidemiology Data

• Country-specific prevalence of infectious bursal disease vaccine, bovine viral diarrhea (BVD), foot and mouth diseases, and swine influenza
•  Country-specific patient pool infectious bursal disease vaccine, bovine viral diarrhea (BVD), foot and mouth diseases, and swine influenza
• Disease progression (pattern analysis)

Surgeons/Physicians Perception Analysis

• Fast turn-around analysis of surgeons’ response to market events and trends
• Pattern analysis of usage of live attenuated vaccines by physicians
• Surgeons’ opinion about products from different companies
• Surgeons’ qualitative inputs on epidemiology data

Brand/ Product Perception Matrix

• Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
• Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

Competitive Intelligence

• The company share analysis of the top players in the live attenuated animal vaccine market in the region
• The crucial developments and strategies of companies inculcated in their portfolio for live attenuated animal vaccine market

Alternative Products: Impact analysis

MMM’s healthcare decision making quadrant is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like patient dynamics (patient pool, epidemiology of disease, preference towards surgeries/alternative therapies) and macroeconomic indicators (number of research laboratories, number of hospitals and clinics, diagnosis rate, treatment rate and healthcare expenditure).

Please fill in the form below to receive a free copy of the Summary of this Report

* First Name :

* Last Name :

* Designation :

* Company :

* Email(Username) :

* Phone :

* Country :

-- Select Country -- India Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antigua Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia Herzegovina Botswana Brazil British Virgin Island Brunei Darussalam Bulgaria Burkina Faso Burundi Cote d'Ivoire Cambodia Cameroon Canada Cape Verde Cayman Isls Central African Republic Chad Chile China Colombia Comoros Congo Cook Island Costa Rica Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Falkland Islands (Malvinas) Fiji Finl France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenl Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Holy See Honduras Hong Kong Special Administrative Hungary Iceland Indonesia Iran (Islamic Republic of Iran) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Special Administrative Region of China Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Micronesia Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherland Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Islands Northern Mariana Islands Norway Occupied Palestinian Territory Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Republic of Korea Republic of Moldova Romania Russian Federation Rwa Saint Helena Saint Kitts Nevis Saint Lucia Saint Pierre Miquelon Saint Vincent the Grenadines Samoa San Marino Sao Tome Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Svalbard Jan Mayen Islands Swazil Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Thailand The former Yugoslav Republic of Macedonia Timor-Leste Togo Tokelau Tonga Trinidad Tobago Tunisia Turkey Turkmenistan Turks Caicos Isls Tuvalu Uga Ukraine United Arab Emirates United Kingdom United Republic of Tanzania United States United States Virgin Isls Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Wallis Futuna Isls Western Sahara Yemen Yugoslavia Zambia Zimbabwe

Comments :

Reports Interested in :North America Live attenuated vaccines Market

* Enter the text from the image to the text box :